Transcriptional effect of CBFA2T3::GLIS2 oncogenic fusion engineering by CRISPR-Cas9 in iPSC-derived hematopoietic cells

inv(16)(p13.3;q24.2) leading to the ETO2-GLIS2 fusion was engineered in iPSC cells. iPSC were then differentiated toward hematopoietic lineage and engrafted in immunodeficient recipient mice. Cells are from CTRL and ETO2-GLIS2 cells at day 13 of in vitro differentiation as well as from engrafted immunodeficient recipient mice that developed leukemia. After CD41+ cell sorting, RNA was extract, followed by library preparation and sequencing.